Senescent Mesenchymal Stem Cells in Myelodysplastic Syndrome: Functional Alterations, Molecular Mechanisms, and Therapeutic Strategies

• Published in: Frontiers in cell and developmental biology Vol. 8; p. 617466
• Main Authors: Chen, Xiaofang, Li, Ningyu, Weng, Jianyu, Du, Xin
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 11-02-2021
• Subjects: bone marrow microenvironment; Cell and Developmental Biology; mesenchymal stem cells; myelodysplastic syndrome; senescence; treatment; senescence; treatment; myelodysplastic syndrome; bone marrow microenvironment; mesenchymal stem cells
• ISSN: 2296-634X; 2296-634X
• DOI: 10.3389/fcell.2020.617466

Myelodysplastic syndrome (MDS) is a group of clonal hematopoietic disorders related to hematopoietic stem and progenitor cell dysfunction. However, therapies that are currently used to target hematopoietic stem cells are not effective. These therapies are able to slow the evolution toward acute myeloid leukemia but cannot eradicate the disease. Mesenchymal stem cells (MSCs) have been identified as one of the main cellular components of the bone marrow microenvironment, which plays an indispensable role in normal hematopoiesis. When functional and regenerative capacities of aging MSCs are diminished, some enter replicative senescence, which promotes inflammation and disease progression. Recent studies that investigated the contribution of bone marrow microenvironment and MSCs to the initiation and progression of the disease have offered new insights into the MDS. This review presents the latest updates on the role of MSCs in the MDS and discusses potential targets for the treatment of MDS.